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Abstract 
Background: Neurotrophins (NT) belongs to a family of growth factors which promotes neurons survival and dif-
ferentiation. Increasing evidence show that NT and their receptor are expressed in lung tissues suggesting a possible 
role in lung health and disease. Here we investigated the expression and functional role of the TrkB/BDNF axis in idi-
opathic pulmonary fibrotic lung (myo)fibroblasts.
Methods: Lung fibroblast were isolated from IPF patients and characterized for the expression of mesenchymal 
markers in comparison to normal lung fibroblasts isolated from non-IPF controls.
Results: BDNF treatment promoted mesenchymal differentiation and this effect was counteracted by the TrkB inhibi-
tor K252a. In this regard, we showed that K252a treatment was able to control the expression of transcription factors 
involved in epithelial to mesenchymal transition (EMT). Accordingly, K252a treatment reduced matrix metalloprotein-
ase-9 enzyme activity and E-cadherin expression while increased cytoplasmic β-catenin expression.
Conclusions: Our results suggest that BDNF/TrkB axis plays a role in EMT promoting the acquisition of (myo)
fibroblast cell phenotype in IPF. Targeting BDNF/TrkB seems to represent a viable approach in order to prevent EMT 
dependent lung fibrosis.
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Background
Idiopathic pulmonary fibrosis (IPF) is a progressive lung 
disease characterized by fibroblast accumulation, colla-
gen deposition, and parenchyma destruction [1, 2]. While 
the exact cause of IPF is unknown, an aberrant activation 
of the alveolar epithelial cell (AEC) is widely recognized a 
key feature associated to IPF pathogenesis [3]. According 
to the current understanding, recurrent AEC injuries ini-
tiate a cascade which leads to aberrant collagen deposi-
tion and tracheobronchial distortion [1, 2]. Despite (myo)
fibroblasts seem to play a critical role in this process, 
their origin within the lung is still controversial. Using 
a mouse model of bleomycin induced pulmonary fibro-
sis in BM  GFP+ chimera mice, Hashimoto et al. demon-
strated that (myo)fibroblasts can directly differentiate 
from circulating bone marrow derived cells homing to 
the lung [4]. In addition, (myo)fibroblasts have also been 
proposed to directly differentiate from TGF-β activated 
resting lung fibroblasts [5]. However, original findings on 
the role of epithelial-to-mesenchymal transition (EMT) 
in pulmonary fibrosis are recently providing new insight 
into the mechanisms of myofibroblast differentiation [6]. 
EMT is defined as a process by which epithelial cells lose 
the cell polarity and cell–cell adhesion, and gain migra-
tory and invasive properties to become mesenchymal 
stem cells [7]. Disruption of cell contacts [7], hypoxia 
and inflammation [8] as well as by oxidative stress [9] are 
commonly recognized as major triggers for EMT.
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EMT is a molecular process by which epithelial cells 
trans-differentiate into motile mesenchymal cells. It con-
tributes pathologically to fibrosis and cancer progression 
[10]. This phenomenon is mediated by specific transcrip-
tion molecules like Twist and Snail (1 and 2-Slug-) that 
activate the EMT during the development of fibrosis and 
cancer [11].
Neurotrophins (NTs), nerve growth factor (NGF), 
brain derived neurotrophic factor (BDNF) neurotro-
phin 3 (NT3) and NT4, are a family of highly conserved 
polypeptide growth factors involved in different cellular 
functions [12]. Besides their role in survival, differentia-
tion, and function of peripheral nerves and brain neurons 
of mammals [12, 13], NTs exert additional activities in 
tumor biology [14, 15] and chronic inflammation [16–
18]. Moreover, previous findings from our group sup-
port a possible role for NT in lung fibrosis [17]. NTs exert 
their effects binding two structurally unrelated recep-
tors: the p75 low affinity receptor, a member of the tumor 
necrosis factor receptor superfamily, and the high affinity 
tyrosine kinase receptors (Trks). While p75 displays the 
capability of binding to all NTs, the Trk receptors exhibit 
ligand selectivity. In particular, TrkB mostly exhibits 
BDNF and NT4 binding specificity [12].
BDNF-dependent TrkB activation has been recently 
associated to EMT-like transformation through the 
Twist-Snail signaling axis, which is dependent on the 
MAPK pathway [19–21]. However, most of these findings 
are based on model of malignant tumor cells in which the 
TrKB–BDNF axis has been demonstrated to be dysregu-
lated. Whether this mechanism is specific for malignant 
transformation it is currently not clear. IPF and cancer 
possess many similarities that suggest the vision of IPF 
as a cancer-like disease. Similar signaling cascades, onco-
gene activation, epigenetic and genetic alterations have 
been reported [22].
Here we aimed to evaluate the potential significance 
of the TrkB–BDNF axis on EMT-dependent (myo)fibro-
blasts differentiation in IPF.
Methods
Human pulmonary fibroblasts cell cultures
Human lung fibroblasts were grown from lung biop-
sies following enzymatic disaggregation by collagenase 
and protease [17]. Lung tissue from patients with IPF 
(n =  10) (mean age ±  SD 61.5 ±  5.3; male 6; female 4) 
who underwent lung biopsies was collected and used to 
generate fibroblast cell cultures. The diagnosis of IPF was 
confirmed based on clinical, radiological and isto-path-
ological findings. Tissue isolated from five donor lungs 
(surgical treatment of pulmonary benign nodules) (mean 
age 72 + 4.4; 3 male; 2 female) was used to generate nor-
mal fibroblasts cell cultures.
From these surgical specimens only five primary fibro-
blast cell cultures from IPF and two from normal lung, 
that displayed good viability and suitable for all the sub-
sequent experiments, was obtained.
Cells were grown in RPMI medium supplemented 
with 10% FBS, 100  units/mL penicillin, 100  µg/mL 
streptomycin and 4  mM l-glutamine (LONZA). The 
medium was replaced twice a week. The cells were incu-
bated at 37  °C in a humidified atmosphere containing 
20%  O2 and 5%  CO2. Fibroblasts were characterized by 
flow cytometry and immunocytochemistry. The pellet 
obtained from the cultures were used for protein and 
RNA extraction. The cultures were used to study the 
functional effects of BDNF on BDNF/TrkB axis. To bet-
ter clarify BDNF effects the serine/threonine protein 
kinase inhibitor (K252a) was used. K252a is considered 
potent inhibitor of all neurotrophin tyrosine protein 
kinase activity [23].
All the patients signed an informed consent.
Western blot analysis
Proteins extracted from fibroblast homogenates were 
separated by 10% SDS–polyacrylamide gel electrophore-
sis and then transferred to a 0.45 μm pure nitrocellulose 
membrane (Bio-Rad) by transfer buffer. The blots were 
blocked with milk at 5% for 1 h and incubated overnight 
at 4  °C with the monoclonal antibodies: anti-Human 
N-cadherin (1  mg/mL) (R&D system), anti-vimentin 
cloneV9 (1:250) (SIGMA), anti-a-actin (N-19) (1:200) 
(Santa Cruz), anti E-cadherin (G-10) (Santa Cruz) and 
anti-cytokeratin, pan (mixture) C2562 (SIGMA), anti-β-
catenin (E-5) (Santa Cruz) and anti-MMP-9 (626–644) 
(Ab-3) (Calbiochem). Primary antibodies-bound mem-
branes were incubated at 4 °C overnight with HRP-conju-
gated secondary antibody (1:4000) anti-mouse (SIGMA). 
Further details are reported in a previous study [19]. For 
detection, an ECL chemiluminescence system (Therma 
Scientific) was used.
Immunofluorescence
For immunofluorescence assay, cells were seeded onto 
multi-chamber slides (Becton–Dickinson) at a density 
of 1   ×   104 cells. After 5  days of treatment, the slides 
were washed in phosphate-buffered saline (PBS) with 
calcium and magnesium, fixed in paraformaldehyde 4% 
for 15  min and permeabilized in Tris buffered saline 
(TBS) 0.05 M pH 7.4 with 1% Triton X-100 for 15 min. 
After blocking in TBS 10% serum for 30  min, slides 
were incubated with the monoclonal antibodies: anti-
Human N-cadherin (1 mg/mL) (R&D system AF 6426), 
anti-vimentin cloneV9 (1:250) (SIGMA), anti-a-actin 
(N-19) (1:200) (Santa Cruz), anti E-cadherin (G-10) 
(Santa Cruz) and anti-cytokeratin, pan (mixture) C2562 
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(SIGMA), for 1  h at 4  °C. After washing in TBS, they 
were incubated with goat anti-rabbit Alexa Fluor 488 
and goat anti-mouse Alexa Fluor 594 antibodies (invitro-
gen) for 30 min and finally washed twice in TBS. Nuclei 
were counterstained with Hoechst 33342 (Sigma) 1 μg/
mL for 10 min. Images were acquired with an Olympus 
BX51 fluorescence microscope and analyzed with I.A.S. 
software (Delta Sistemi, Legnano, Italy). The brightness 
and contrast of the acquired images were adjusted, and 
the figures were generated using Adobe Photoshop 7.0. 
Cells not treated with RA were considered to be negative 
controls.
Immuno‑fluorescent method for flow cytometry
Flow cytometry was used in order to evaluate the expres-
sion of cell surface markers on cultured fibroblast using 
a FACS Calibur cyto-fluorimeter (Becton–Dickinson, 
Sunnyvale, CA, USA) (FCM). Briefly, cells were treated 
with the BDNF (10 ng/mL) (SIGMA) and TrKB inhibitor 
K252a (3 nM) (SIGMA) for 10 days. After the treatment 
cells were stained with specific primary antibody fol-
lowed by a secondary FITC-conjugated antibody before 
to be analyzed by FCM.
RNA extraction and semi‑quantitative RT‑PCR analysis
RNA extraction and cDNA synthesis were performed 
as previously described [24]. The 18S RNA was used to 
normalize the amount of total RNA present in each reac-
tion. Specific sequences targeted against Snail gene for 
5′gcgcagctctaatccaga-3′ and rev5′-atctccggaggtgggatg-3′; 
Twist gene for 5′-agctacgccttctggtct-3′  and rev 
5′-ccttctctggaacaatgacatc-3′ and Zeb gene for: 5′-gggag-
gagcagtgaaagaga-3′, Rev: 5-tttcttgcccttcctttctg-3′, were 
obtained from Sigma Aldrich. PCR products were visual-
ized on a 2% agarose gel after ethidium bromide staining. 
Three independent experiments were performed for each 
sample. The intensities of the bands on gels were meas-
ured by densitometry, using the ImageJ software (version 
1.32j).
Zymography
Proteins were separated by electrophoresis under dena-
turing (SDS), non-reducing conditions, with a 10% pol-
yacrylamide gel containing 1–2  mg/mL gelatin. After 
electrophoresis, the gel was washed and incubated over-
night in an appropriate activation buffer at 37 °C. The gel 
was then stained with  Coomassie® Brilliant Blue R250 
(Kodak) in 30% methanol, 7.5% acetic acid and washed 
with water at 22 °C for 20 min. The MMPs were detected 
as clear bands against a blue background of un-degraded 
substrate. The clear bands in the gel were quantified by 
densitometry.
Trypan blue exclusion test of cell viability
The Trypan blue exclusion test was used to determined 
viable cell number in cell suspension. Damaged or not 
viable cell incorporated the trypan blue dye and assumed 
a blue staining.
IPF fibroblast cell line were seeded in 60  mm Petri 
dishes at density of 2 × 105 cells in RPMI medium sup-
plemented with 5% FBS. RPMI1640 medium with BDNF 
(10 nM) with or without k252a inhibitor were added in the 
cell separately, as described above. Effects of treatment on 
cell migration the IPF fibroblast cell line were evaluated 
after 24, 48 and 120 h. The number of viable cells present 
in a cell suspension was obtained by trypan-blue assay 
(Sigma Aldrich). Briefly, 10  mL of cells was aseptically 
transferred to a 0.2  mL clear Eppendorf tube and incu-
bated for 2 min at room temperature with a equal volume 
of trypan blue solution. The cell number was determined 
by counting the viable cells in a hemocytometer. The per-
centage of viable cells from each tube after incubation 
with material extracts was obtained by applying the fol-
lowing equation: %viable cells = (VC/TC)× 100, where 
VC =  viable cells counted and TC =  total cells counted 
(stained plus unstained cells). The experiments were per-
formed in triplicate.
Wound healing assay
Fibroblast from IPF lungs (UIP/IPF) were seeded in 60 mm 
Petri dishes at density of 5 × 105 cells. After 48 h, the cells 
were confluent and at a concentration of 1 × 106 cells/mL 
and cultured in medium containing 10% FBS to nearly 
confluent cell monolayers. The cell were then starved over-
night in serum free RPMI-1640 medium. A linear wound 
was generated in the monolayer with a sterile 100 μL plastic 
pipette tip. Any cellular debris was removed by washing the 
coverslips with phosphate buffer saline (PBS). RPMI1640 
medium with BDNF (10 nM) or k252a inhibitor were added 
in the cell separately, cell lines cultured with RPMI1640 
alone were considered as controls (C). Effects of treatment 
on cell migration were evaluated for 120  min. Three rep-
resentative images from each point of the scratched areas 
under each condition were photographed to estimate the 
relative migration cells. Migration ability was assessed by 
measuring changes in the size of the wounded areas. All the 
experiments were performed in triplicate.
Statistical analysis
Data are expressed as mean ± SD. Statistical significance 
was assessed using unpaired Student t test. Multiple 
groups were analyzed by the one-way ANOVA tests. Sta-
tistical analysis was performed by using the SPSS soft-
ware (IBM SPSS Statistics US) and a p value < 0.05 was 
considered significant.
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Results
Lung fibroblast from human IPF show higher levels of EMT
Human primary cell lines of fibroblast derived from 
either normal and IPF lungs were assessed for EMT 
markers using flow cytometry.
N-cadherin, vimentin and α-actin were used as mes-
enchymal cell markers, whereas E-cadherin and pan-
cytokeratin were used as epithelial cell markers.
We observed that approximately 35% of our cultured 
fibroblasts derived from IPF lung expressed N-cadherin 
where almost all of them 99% were positive for vimentin. 
In comparison, only 24% of the normal control fibroblast 
express N-cadherin and not more than 95% were positive 
for vimentin (Fig. 1).
Regarding α-actin we found its expression in almost 
(19–50%) of the IPF derived fibroblast compared to the 
2% positive cells observed in normal control fibroblasts 
cell lines (Fig. 1).
These results indicate that fibroblast cultures obtained 
from IPF lungs are more enriched with cells expressing 
EMT markers compared to normal fibroblast cell lines. 
In addition, the percentage of cells expressing epithelial 
b
a
(%) N-Cadherin Vimentin a-actin E-cadherin Pan-
Citokeratin
Normal 
fibroblasts
22+4 93+6 2+2 6+2 2+2
IPF/UI 38+12 92+8 22+4* 4+2 8+4
Negative 1+1 2+2 1+1 2+1 2+4
Fig. 1 Analysis of mesenchymal and epithelial markers in representative idiopathic pulmonary fibrosis (IPF/UIP1 and 2) and normal fibroblast 
(FibroN2) cell cultures using flow cytometry. a Analysis of mesenchymal and epithelial markers in representative idiopathic pulmonary fibrosis (IPF/
UIP1 and 2) and normal fibroblast (FibroN2) cell cultures using flow cytometry. b Panel B represents the mean values ± SD of the results obtained 
in the two normal fibroblast cell cultures considered as controls in comparison with the five fibroblast cell cultures obtained from IPF patients. * 
p < 0.01 versus normal fibroblast cell cultures. Negative sample was generated with the corresponding isotope (negative)
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markers such as E-cadherin and pan-cytokeratin was 
extremely low in both condition (<  5%) confirming the 
absence of epithelial cell contamination in our fibroblast 
cell cultures (Fig. 1).
BDNF/Trk axis promotes EMT associated cadherin 
switching in lung fibroblast
Previous work from our group show that TrKB and 
BDNF are highly expressed on human IPF lung fibroblast 
[17]. Here, we investigate the effects of TrKB stimulation 
and inhibition in terms of fibroblast mesenchymal dif-
ferentiation. Using fluorescence microscopy we showed 
that the addition of BDNF (10 ng/mL) to culture medium 
promote the increase of N-cadherin expression in human 
lung fibroblast (Fig. 2). This effect was more pronounced 
in fibroblasts derived from IPF lung compared with the 
normal control (Fig. 3). This phenomenon may be due to 
the different phenotype and activity of IPF fibroblasts in 
comparison to normal ones. The N-cadherin expression 
was associated with TrKB activation since the treatment 
with the TrK inhibitor K252a (3  µM) attenuated this 
effect (Fig. 2 and 3).
Effect of K252a inhibitor on the BDNF/TrKB axis
In order to assess the functional effect of BDNF and its 
K252a dependent inhibition on human IPF fibroblast cell 
cultures we assessed cell vitality by trypan-blue exclusion 
cell count and wound healing assay. We observed that the 
addition of K252a to the medium, inhibited cell prolifera-
tion of about 70% in a time dependent way, in compari-
son with cell lines treated with BDNF (Fig. 4a). Moreover 
by wound healing assay, we demonstrated that migration 
of cell, into the wounded area, was reduced by K252a 
(Fig. 4b).
In addition, we assessed the mRNA levels of Zeb, 
Snail and Twist in IPF cell line by PCR. The addition of 
BDNF (10 nM) to culture medium is able to significantly 
increase mRNA expression of Zeb, Snail and Twist in 
comparison to cell line treated with K252a inhibitor. On 
the contrary, K252a induced a decrease in mRNA expres-
sion of same genes in comparison to not treated cells 
(Fig. 5a).
We have also assessed the matrix metalloproteinase-9 
(MPP-9) and β-catenin protein expression. The results, 
obtained by zymography, showed that the enzyme activ-
ity of MPP-9 was reduced after k252a treatment in 
comparison to BDNF and no treated cell lines (Fig. 5b). 
Moreover BDNF induced an increased cytoplasmic 
expression of the β-catenin protein that was not induced 
K252a. The nuclear expression of β-catenin was not 
affected by the presence of BDNF or K525a (Fig. 5c).
Discussion
Increased expression of mesenchymal and reciprocal low 
expression of epithelial markers induces profound altera-
tion in epithelial cell polarity and morphology, resulting 
into epithelial-to-mesenchymal transition (EMT) [25, 
26]. The EMT has been considered to be critical biologi-
cal process in epithelial tumor invasion, progression and 
metastasis. Recent data also implicates TrkB as a regula-
tor of EMT [19, 27] and a direct role in the tumor pro-
gression [14, 28–31]. More recently, the high affinity 
TrkB receptor activation, induced by its specific ligand 
BDNF, has been demonstrated to induce an EMT-like 
transformation in epithelial cells through a Twist-Snail 
signaling axis, which is dependent on the MAPK pathway 
[21]. Moreover, the inverse correlation between TrkB and 
E-cadherin expression has been strictly linked to more 
aggressive phenotype in non small cell lung cancer [19].
The TrkB receptor has been reported to possess an 
essential role in airway branching and alveolarization 
[32], and NTs and their receptors have also been con-
sidered as intriguing molecules in several adult lung dis-
eases including IPF [33–36]. However, apart from these 
limited results there is no clear data about the biological 
role the BDNF/TrkB signaling pathway in idiopathic pul-
monary fibrosis.
Our results, for the first time, demonstrate that the 
activation of BDNF/TrkB signaling pathway plays an 
important role in EMT in primary fibroblast cell cultures 
from fibrotic lung and that TrkB may address fibroblasts 
phenotype.
These data provide new insight that fibroblasts can also 
form locally by EMT during lung fibrosis. Therefore, a part 
of fibroblasts located in fibrotic lung may derive from epi-
thelial cells. Epithelium, with the damage of basal mem-
brane, during the fibrotic process within the lung, detach 
from their functional units losing their morphogenic fea-
tures. It is well known that type II alveolar epithelial cells 
possess proliferative potential [37]. In  vivo and in  vivo 
results underline that these cells may be progenitors of 
mesenchymal cells contributing to the pool of expanded 
fibroblasts during lung injury in mice [37]. Local secretion 
of pro EMT cytokines, usually found in the transitional 
environment, may drive these effects. BDNF may have a 
role in this transition, by binding high affinity TrkB recep-
tor. BDNF is able to induce an increase in mesenchymal 
markers, but its inhibition, by specific receptor antago-
nists, promote epithelial marker re-expression [19, 30, 38].
The expression of both mesenchymal and epithelial 
markers also observed in our results are in line with the 
observation of different authors that described their co-
localization, in the fibrotic lung [25, 37, 39].
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Several line of evidences suggest that IPF fibroblasts 
are able to respond to different inflammatory and non-
inflammatory stimuli like several cytokines. Interestingly, 
BDNF was able to activate Jak/Stat pathway that was also 
activated by the pro-fibrogenetic and mitogenic IL6 [20, 
34, 40, 41]. Therefore, BDNF represents an attractive 
Fig. 2 K252a by BDNF/TrkB axis modulate the mesenchymal and epithelial markers in fibroblast cell line. Representative immunofluorescence pic-
tures showing that BDNF binding to TrKB receptor up-regulates the expression of mesenchymal markers. These effects are inhibited by the specific 
TrkB receptor selective inhibitor K252a
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molecule able to participate to the complex pro-fibro-
genetic cytokine network that participate to lung fibrosis 
in IPF.
These data are in line with the hypothesis that 
EMT may be part of mechanisms involved in fibro-
blast and (myo)fibroblast accumulation within the 
Fig. 3 Cell signaling in idiopathic pulmonary fibrosis. Western blot analysis of the expression of mesenchymal marchers in homogenates of 
fibroblast cell cultures obtained from normal and IPF subjects. As noticeable, the expression of mesenchymal marker protein was decreased in the 
presence of the TrkB receptor blocker K252a in IPF fibroblast homogenates (*p < 0.001; **p < 0.05; ***p < 0,01 vs BDNF treated and controls) (a). 
Contrarily, the presence of the BDNF increased α-actin expression in normal fibroblast (*p < 0.001; **p < 0.01 vs controls) (b). The addition of TrkB 
receptor selective inhibitor K252a reduces the phosphorylation of AKT in IPF fibroblasts (*p < 0.05; **p < 0.001 vs K252a treated cells) (c). This effect 
was slightly noticeable in normal fibroblasts (*p < 0.01; **p < 0.05 vs K252a treated cells) (d). Results were statistically evaluated by using Student’s t 
test
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lung in idiopathic pulmonary fibrosis. In experimen-
tal models, EMT have been considered as a marker 
of epithelial dysfunction and damage in response to 
inflammatory stimuli but may be also considered as a 
mechanism by which (myo)fibroblasts can be gener-
ated, underlining different sources and phenotype of 
fibroblasts during fibrosis. EMT, in this context, could 
participate in an aberrant epithelial–mesenchymal 
communication, through which the activated alveo-
lar cells may release factors that promote and main-
tain fibro-genesis and allow fibroblasts to survive. 
Thus fibrosis is a complex phenomenon shared by 
failing organs, EMT may be considered a pathophysi-
ological dysfunction that lead to epithelial unit loss, 
and conversion of collagen synthesis. It could not be 
excluded that different differentiated cells within the 
lung (endothelium, or myocytes) could also transition 
to fibroblasts when necessitated, participating to lung 
remodeling.
Conclusions
To summarize, the TrkB pathway represents a complex 
signaling network that is of interest to understand the 
pathophysiology of different proliferative, inflammatory 
Fig. 4 Effect of the TrkB receptor blocker K252a on fibroblast cell growth. a K252a induced a decrease in cell growth in comparison to cell line 
treated with BDNF and no treated cells after 120 h (C). The number of viable cells present in a cell suspension was obtained by tryplan-blue staining. 
Histogram at the bottom represents the number of fibroblast cell viability obtained in the Trypan blue exclusion test after 24 h of treatment with 
indirubin. The asterisk indicates significant difference compared to the BDNF treated cell and control group (*p < 0.05, ** p < 0.01, ANOVA followed 
by Tukey’s test). Each bar represents the mean ± SD of three independent experiments. b Migration ability of fibroblast cell lines determined by 
wound healing assay. Cell lines treated with BDNF have a higher motility into the wounded area, in comparison those treated with TrkB inhibitor 
K252a (black rectangles). Results were statistically evaluated by Students t test (*p < 0.05 K252a treated cells vs controls, **p < 0.01 BDNF treated 
cells vs controls). The amount of migrated cells was measured by ImageJ software (version 1.32j)
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and degenerative lung disorders and to the potential 
design of novel therapeutic treatments and combination 
therapies.
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